Abstract
Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Current Drug Safety
Title:Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Volume: 8 Issue: 1
Author(s): Antonio Siniscalchi, Luca Gallelli, Simona Loizzo, Avenoso Tiziana, Emilio Russo and Giovambattista De Sarro
Affiliation:
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Abstract: Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca, Loizzo Simona, Tiziana Avenoso, Russo Emilio and Sarro Giovambattista De, Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome, Current Drug Safety 2013; 8 (1) . https://dx.doi.org/10.2174/1574886311308010010
DOI https://dx.doi.org/10.2174/1574886311308010010 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Coenzyme Q10 in Neurodegenerative Diseases
Current Medicinal Chemistry Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology AAV as An Immunogen
Current Gene Therapy Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Editorial
Current Medical Imaging Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design 2,3-Disubtituted Thiazolidin-4-ones: Novel Class of Anticonvulsant Agents
Letters in Drug Design & Discovery Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Meet Our Editorial Board Member
Current Neuropharmacology Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Damaged Proteins Bearing L-Isoaspartyl Residues and Aging: A Dynamic Equilibrium Between Generation of Isomerized Forms and Repair by PIMT
Current Aging Science